{"id":"W2921561928","doi":"10.1016/j.neuron.2019.02.005","title":"Ketamine: A Paradigm Shift for Depression Research and Treatment","year":2019,"lang":"en","type":"review","venue":"Neuron","topic":"Treatment of Major Depression","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Janssen Research and Development; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Center for Research Resources; Vistagen Therapeutics; Valeant Pharmaceuticals International; Harvard University; Taiho Pharmaceutical; Sunovion; Broad Institute; Yale Center for Clinical Investigation, Yale School of Medicine; Eli Lilly and Company; Icahn School of Medicine at Mount Sinai; Avanir Pharmaceuticals; U.S. Department of Veterans Affairs; BlackThorn Therapeutics; Teva Pharmaceutical Industries; Yale University; Brain and Behavior Research Foundation","keywords":"Ketamine; Paradigm shift; Depression (economics); Psychology; Neuroscience; Cognitive science; Epistemology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3074628548042871,"score_gpt":0.476674522636001,"score_spread":0.1692116678317139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}